2021
DOI: 10.21873/anticanres.14809
|View full text |Cite
|
Sign up to set email alerts
|

Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(8 citation statements)
references
References 0 publications
0
8
0
Order By: Relevance
“…Currently, anti-angiogenic therapy has been used clinically in the adjuvant setting of cancer patients ( 47 ). Efforts to develop novel anti-angiogenic or anti-lymphangiogenic agents primarily focused on targeting VEGF/VEGFR signaling, a central regulator, despite the presence of other signaling pathways involved in angiogenesis and lymphangiogenesis ( 7 , 20 , 26 , 27 ). Increasing evidence is showing that benzimidazoles readily interact with signaling molecules and exhibit a broad spectrum of biological activities including anti-cancer properties ( 48 ).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Currently, anti-angiogenic therapy has been used clinically in the adjuvant setting of cancer patients ( 47 ). Efforts to develop novel anti-angiogenic or anti-lymphangiogenic agents primarily focused on targeting VEGF/VEGFR signaling, a central regulator, despite the presence of other signaling pathways involved in angiogenesis and lymphangiogenesis ( 7 , 20 , 26 , 27 ). Increasing evidence is showing that benzimidazoles readily interact with signaling molecules and exhibit a broad spectrum of biological activities including anti-cancer properties ( 48 ).…”
Section: Discussionmentioning
confidence: 99%
“…To date, several VEGF/VEGFR-targeting agents have been approved by the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA) or in the development pipeline for the treatment of certain types of cancer. These included monoclonal antibodies bevacizumab (Avastin ® ) and ramucirumab (Cyramzar ® ) ( 22 , 23 ) and small molecule inhibitors such as sunitinib (Sutent ® ), sorafenib (Nexavar ® ), axitinib (Votrient ® ), pazopanib (Votrient ® ) regorafenib (Stivarga ® ) and lenvatinib (Lenvina ® ) ( 24 27 ).…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, phase II trials have demonstrated that regorafenib is safe and effective in the elderly population [ 64 , 65 ]. So far, prospective trials combining regorafenib with chemotherapy have not demonstrated a survival advantage, but ongoing trials are still evaluating this potential regimen [ 66 ].…”
Section: Vascular Endothelial Growth Factor (Vegf)mentioning
confidence: 99%
“…The median OS was 9.3 months with fruquintinib versus 6.6 months among patients who received placebo. Other TKIs with activity against VEGF/VEGFR are currently being evaluated for mCRC [ 66 ].…”
Section: Vascular Endothelial Growth Factor (Vegf)mentioning
confidence: 99%
“…[27][28][29] The sorafenib-fluoro-congener, regorafenib (Stivarga ® , BAY-73-4506) (II), is also a multikinase inhibitor that is used for metastatic colorectal cancer through the inhibition of several protein kinases related to the oncogenic and angiogenic pathways. [28][29][30] Ripretinib (Qinlock™, DCC-2618) (III), a diaryl urea pyridopyridone derivative, is a multikinase inhibitor targeting VEGFR-2, BRAF, PDGFR-β, and KIT that is used for the treatment of gastrointestinal stromal tumors (GISTs). [16] Lenvatinib (Lenvima ® ) (IV), a cyclopropyl phenylurea quinoline derivative, is a multikinase inhibitor targeting VEGFRs, FGFRs, and PDGFR-α approved for the treatment of metastatic differentiated thyroid cancer (DTC) as well as HCC.…”
Section: Introductionmentioning
confidence: 99%